Pulling SEC filings + quote and writing the call…

LifeMD, Inc.
Next earnings Aug 3, 2026 · consensus $-0.13 EPS, $50.2M rev
Last earnings +2.7% on 2026-05-06
Revenue grew 25.3% YoY.
Quality fundamentals and an attractive price line up (~126% below fair value) — the rarer case where both the business and the entry look good.
Sources: SEC EDGAR (CIK 0000948320, latest 10-Q filed 2026-05-06) · EODHD · as of 6/25/2026, 11:19:04 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
LifeMD, Inc. shows $194M in FY2025 revenue (+25.3% YoY), a 7.4% net margin, and 62.0% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $92.9M | $119M | $153M | $155M | $194M |
| Gross profit | $74.9M | $100M | $134M | $133M | $166M |
| Operating income | -$54.3M | -$43.4M | -$14.5M | -$20.4M | -$7.67M |
| Net income | -$60.9M | -$45.5M | -$20.6M | -$21.4M | $14.4M |
| Diluted EPS | — | — | — | -$0.60 | $0.25 |
| Net margin | -65.6% | -38.3% | -13.5% | -13.8% | 7.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1071 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-06-01 | Sripad Umesh Chief Technology Officer | Award | 75.0K | |
| 2026-05-11 | Kavthekar Atul Chief Financial Officer | Award | 338K | |
| 2026-03-30 | Pisano Christopher A Chief Marketing Officer | Award | 200K | |
| 2025-12-09 | FRIEDEMAN JESSICA Chief Marketing Officer | Sell | 15.0K @ $3.61 | $54.2K |
| 2025-10-06 | Strawn John R Jr Director | Award | 22.4K | |
| 2025-10-06 | LAROVERE JOAN Director | Award | 22.4K | |
| 2025-10-02 | DiTrolio Joseph Director | Award | 22.4K | |
| 2025-10-02 | MACRAE CALUM ARCHIBALD Director | Award | 22.4K |